CTI BioPharma
64
1
2
33
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.2%
27 terminated/withdrawn out of 64 trials
55.0%
-31.5% vs industry average
22%
14 trials in Phase 3/4
55%
18 of 33 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (64)
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Role: collaborator
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Role: collaborator
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Role: collaborator
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
Role: lead
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
Role: lead
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
Role: lead
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
Role: lead
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
Role: lead
Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
Role: lead
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
Role: lead
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
Role: lead
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects
Role: lead
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
Role: lead
Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects
Role: lead
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Role: collaborator
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
Role: collaborator
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Role: lead
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
Role: collaborator
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Role: lead
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Role: lead